Breaking news on crohns
FDA Approval Of Cimzia(R) For Crohn's Disease Represents Latest Milestone For Nektar's PEGylation Technology Platform published
Thu, 24 Apr 2008 00:00:00 PDT
The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA.
Cimzia® Approved In United States For Crohn's Disease published
Wed, 23 Apr 2008 10:00:00 PDT
According to a press release from UCB on April 22, 2008, a newpegylatedanti-TNFα, will be made available in the United States under thename Cimzia® in the next few days. This will be a new,promising option for patients suffering from moderate to severe Crohn'sDisease. Crohn'sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
FDA Approves Cimzia To Treat Crohn's Disease published
Wed, 23 Apr 2008 04:00:00 PDT
A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies. This product was approved with a Medication Guide.Crohn's disease is a chronic, inflammatory bowel disease that affects more than 1 million men and women worldwide. It has no cure and its cause is unknown.
Omega-3's No Help For Crohn's Sufferers published
Wed, 09 Apr 2008 03:00:00 PDT
An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease. The research is published in the April 9 Journal of the American Medical Association.
For Crohn's Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse published
Tue, 08 Apr 2008 13:00:00 PDT
Administrationof omega-3 fatty acid supplements did not appear to improve the rate ofrelapse in patients with Crohn's disease, according to a study releasedon April 9, 2008 in JAMA. Crohn'sDisease is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
Large Multi Center Study Suggests New Genetic Markers For Crohn's Disease published
Fri, 28 Mar 2008 00:00:00 PDT
What is believed to be the largest study of its kind for the genetic roots of inflammatory bowel diseases has suggested new links to Crohn's Disease as well as further evidence that some people of Jewish descent are more likely to develop it.
CHMP Upholds Negative Opinion For The EU Application For Cimzia(R) In The Treatment Of Crohn's Disease published
Mon, 24 Mar 2008 12:00:00 PDT
UCB announced that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn's disease, a chronic and debilitating inflammatory disease.
CHMP Upholds Negative Opinion For The EU Application For Cimzia® In The Treatment Of Crohn's Disease published
Fri, 21 Mar 2008 01:00:00 PDT
UCB announced today that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn's disease, a chronic and debilitating inflammatory disease.
Food For Life Baking Co., Inc. Recalls Spelt Bread , California - Product Contains Undeclared Wheat published
Thu, 20 Mar 2008 01:00:00 PDT
Food For Life Baking Company of Corona, California is voluntarily recalling 2,241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat. People who have allergies to wheat or those with Celiac Disease may run the risk of a serious or life threatening allergic reaction if they consume spelt products. The recalled products were sold nationwide through health food distributors and natural food retailers.
Caspase-12: MUHC Researcher Finds New Defense Mechanism Against Intestinal Inflammation published
Thu, 13 Mar 2008 04:00:00 PDT
The body's first line of defence against pathogenic bacteria that we ingest may not be the immune system but rather the cells that line the intestine. This surprising conclusion is just one facet of a study by Dr. Maya Saleh, a researcher at the Research institute of the McGill University Health Centre, published in the journal Cell Host & Microbe on March 12.
Hope For Crohn's Patients With Fistulas Found In HUMIRA/Adalimumab published
Tue, 11 Mar 2008 00:00:00 PDT
At the recent European Crohn's and Colitis Organization (ECCO) annualmeeting in Lyon, France, Abbott Laboratories announced that HUMIRA(Adalimumab) is successful in the treatment of fistulas in susceptibleCrohn's patients. Crohn'sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract.
Early Data On Cimzia® Shows Promise In Crohn's Patients Without Infliximab published
Thu, 06 Mar 2008 00:00:00 PDT
Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn's and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia® (certolizumab pegol) is effective in Crohn's patientsshowing intolerance or no response to infliximab. Crohn'sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
New Treatment Strategy For Crohn's Disease Shows Promise published
Mon, 03 Mar 2008 00:00:00 PDT
When treating patients with Crohn's disease, early use of an intensivecombined immunosuppression (CI) in combination withconventional management is more effective than the current standard,treatment with corticosteroids. These outcomes were reported in anArticle in the February 23, 2008 issue of The Lancet.
Inflammatory Bowel Disease May Mimic Gynecological Disorders In Its Clinical Presentation published
Mon, 25 Feb 2008 03:00:00 PDT
Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis. When the disease involves the small bowel, it usually has a benign course, but in rare circumstances, it may present as abdominal emergency. Invasive bowel endometriosis can present as bowel obstruction.
Improved Treatment For Crohn's Disease published
Fri, 22 Feb 2008 03:00:00 PDT
An international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease."Our study clearly demonstrated that this alternative treatment method was more effective at inducing disease remission than the conventional method," said Dr.
Asacol 800mg MR Tablets Dosed At 4.8g/Day Herald Fast Symptom Relief And Improved Quality Of Life For Moderately Active UC Patients published
Fri, 08 Feb 2008 01:00:00 PDT
Procter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of mild to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn's ileo-colitis patients.1 The ASCEND I and II clinical trials have shown that Asacol 800mg MR tablets at 4.8 g/day provide symptom relief* 10 days faster (median time) than a mesalazine 400mg at 2.
FDA Approves Tysabri® For The Treatment Of Moderate-To-Severe Crohn's Disease published
Mon, 21 Jan 2008 00:00:00 PDT
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for TYSABRI® (natalizumab).
FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease published
Tue, 15 Jan 2008 04:00:00 PDT
The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies. Crohn's disease patients using the drug must be enrolled in a special restricted distribution program called the Crohn's Disease-Tysabri Outreach Unified Commitment to Health (CD TOUCH) Prescribing Program.
Intestinal Inflammation Decreased By Il-22 Gene published
Thu, 03 Jan 2008 02:00:00 PDT
There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General Hospital, Boston, have established that IL-22 ameliorates disease in a mouse model of UC.Expression of IL-22 is much higher in the intestines of individuals with CD than UC.
Scientists Find How Bacteria In Cows' Milk May Cause Crohn's Disease published
Mon, 17 Dec 2007 00:00:00 PDT
Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.
Bacteria In Cows' Milk May Cause Crohn's Disease published
Tue, 11 Dec 2007 04:00:00 PDT
Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli bacteria found in the body. E.coli is known to be present within Crohn's disease tissue in increased numbers.
Differing Physician And Patient Perceptions Regarding Impact Of UC Revealed by Nationwide Survey published
Mon, 10 Dec 2007 02:00:00 PDT
Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented at the 2007 Crohn's & Colitis Foundation's 6th Annual Advances in the Inflammatory Bowel Diseases conference.
Callisto Announces Presentation On Guanilib At 2007 Crohn's And Colitis Foundation National Research And Clinical Conference published
Wed, 05 Dec 2007 05:00:00 PDT
Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical data on Guanilib at the Crohn's and Colitis Foundation National Research and Clinical Conference - 6th Annual Advances in the Inflammatory Bowel Diseases during Dec. 6-9, 2007 in Aventura, Florida. Dr.
CHMP Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohn's Disease published
Mon, 19 Nov 2007 00:00:00 PDT
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease. This decision is on the appeal the companies filed following a previous negative opinion adopted by the CHMP earlier in 2007.
UCB To Appeal European Negative Opinion On CIMZIA(R) For The Treatment Of Patients With Crohn's Disease published
Fri, 16 Nov 2007 11:00:00 PDT
UCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with Crohn's disease. UCB plans to utilise the appeal process to request a CHMP re-examination of the submission. A decision is expected during the first half of 2008.
)
|
|
